NASDAQ:ADXN Addex Therapeutics (ADXN) Stock Price, News & Analysis → This consistently signaled gains of 453%... 610%... and even 1036%... (From Insiders Exposed) (Ad) Free ADXN Stock Alerts $12.80 +0.45 (+3.64%) (As of 03/28/2024 ET) Add Compare Share Share Today's Range$12.25▼$12.9250-Day Range$7.05▼$13.1052-Week Range$5.00▼$23.40Volume4,843 shsAverage Volume9,755 shsMarket Capitalization$12.67 millionP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOwnershipSEC FilingsShort InterestSocial Media Get Addex Therapeutics alerts: Email Address Addex Therapeutics MarketRank™ Stock AnalysisAnalyst RatingN/AUpside/DownsideN/AShort InterestHealthy1.17% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.43Based on 3 Articles This WeekInsider TradingN/AProj. Earnings GrowthGrowingFrom ($17.20) to ($11.80) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.0.23 out of 5 starsMedical Sector917th out of 938 stocksPharmaceutical Preparations Industry412th out of 422 stocks N/A Analyst's Opinion Consensus RatingThere is not enough analysis data for Addex Therapeutics. Previous Next 3.0 Short Interest Percentage of Shares Shorted1.17% of the float of Addex Therapeutics has been sold short.Short Interest Ratio / Days to CoverAddex Therapeutics has a short interest ratio ("days to cover") of 1.2, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Addex Therapeutics has recently increased by 41.67%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldAddex Therapeutics does not currently pay a dividend.Dividend GrowthAddex Therapeutics does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for ADXN. Previous Next 1.9 News and Social Media Coverage News SentimentAddex Therapeutics has a news sentiment score of 0.43. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.61 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 3 news articles for Addex Therapeutics this week, compared to 0 articles on an average week.MarketBeat FollowsOnly 1 people have added Addex Therapeutics to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days. Previous Next 0.8 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Addex Therapeutics insiders have not sold or bought any company stock.Percentage Held by Insiders15.00% of the stock of Addex Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by InstitutionsOnly 16.14% of the stock of Addex Therapeutics is held by institutions. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Addex Therapeutics are expected to grow in the coming year, from ($17.20) to ($11.80) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Addex Therapeutics is -0.66, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Addex Therapeutics is -0.66, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioAddex Therapeutics has a P/B Ratio of 1.60. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here Ad Crypto Swap ProfitsGrab Your Free Bitcoin Today!And my special guest is willing to give you $10 in Bitcoin (BTC) if you take it seriously. Right now is a very important time to pay attention to what we are doing and what is happening. If you wait... it will be too late. This week we are holding several workshops and if you attend and pay attention my special guest is going to send you $10 in Bitcoin.>> Register right here About Addex Therapeutics Stock (NASDAQ:ADXN)Addex Therapeutics Ltd, a development-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule pharmaceutical products for central nervous system (CNS) disorders in Switzerland. The company focuses on the discovery of G-protein coupled receptors. Its lead programs include Dipraglurant for the treatment of Parkinson's disease levodopa-induced dyskinesia, and dystonia; ADX71149 for epilepsy and undisclosed CNS disorders; and GABAB PAM for pain, anxiety, and addiction. It has license and collaboration agreement with Janssen Pharmaceuticals Inc.; Indivior PLC; and The CharcotMarieTooth Association. The company was formerly known as Addex Pharmaceuticals Ltd. Addex Therapeutics Ltd was founded in 2002 and is headquartered in Geneva, Switzerland.Read More ADXN Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart ADXN Stock News HeadlinesMarch 29, 2024 | americanbankingnews.comAddex Therapeutics Ltd (NASDAQ:ADXN) Sees Large Growth in Short InterestMarch 14, 2024 | globenewswire.comAddex to Present at the Bio-Europe Spring 2024 ConferenceMarch 29, 2024 | Crypto 101 Media (Ad)Crypto Market Preps For Trillions Worth of Inflows! Bitcoin is rapidly approaching new ALL-TIME HIGHS… The market is buzzing after recent approval of spot Bitcoin exchange-traded funds (ETF). Top analysts predict these ETFs will attract trillions of dollars worth of inflows over the next few years… And as Bitcoin rallies, we could see other smaller coins rise to heights never seen before.February 22, 2024 | benzinga.comAddex Therapeutics Stock (NASDAQ:ADXN), Short Interest ReportJanuary 31, 2024 | finance.yahoo.comAddex Enters into At-The-Market ADS Offering Agreement with H.C. Wainwright & Co. LLC.January 9, 2024 | finance.yahoo.comAddex to Present at the Swiss Equities Baader ConferenceJanuary 5, 2024 | finance.yahoo.comAddex to Present at Biotech Showcase™ 2024December 23, 2023 | thestreet.comAddex Therapeutics LtdMarch 29, 2024 | Crypto 101 Media (Ad)SHOCKING Crypto Leak…A shocking leak has revealed tech giant Microsoft's plans to add crypto support to future products. If the plans in these leaked internal documents pan out, we could see prices skyrocket for Bitcoin, Ethereum, XRP and MORE… The coupling of gaming and cryptocurrency could absolutely transform digital finance as we know it in 2024. December 20, 2023 | finanznachrichten.deAddex Therapeutics: Addex Shareholders Approve All Resolutions at Extraordinary General MeetingDecember 20, 2023 | finance.yahoo.comAddex Shareholders Approve All Resolutions at Extraordinary General MeetingDecember 14, 2023 | finance.yahoo.comAddex Creates Treasury SharesNovember 29, 2023 | msn.comAddex Therapeutics GAAP EPS of -CHF0.03, income of CHF0.33MNovember 29, 2023 | markets.businessinsider.comAddex Therapeutics Posts Narrower Loss In Q3 - Quick FactsNovember 29, 2023 | finance.yahoo.comAddex Reports Q3 2023 Financial Results and Provides Corporate UpdateNovember 28, 2023 | finance.yahoo.comAddex Convenes Extraordinary General MeetingNovember 23, 2023 | finance.yahoo.comAddex Therapeutics to Release Third Quarter 2023 Financial Results and Host Conference Call on November 29, 2023November 14, 2023 | finance.yahoo.comAddex ADX71149 Epilepsy Phase 2 Study Completes Recruitment of PatientsNovember 2, 2023 | finance.yahoo.comAddex Announces Participation in the Bio-Europe 2023 ConferenceOctober 21, 2023 | finanznachrichten.deAddex Therapeutics: Addex Completes ADS Ratio ChangeOctober 20, 2023 | finance.yahoo.comAddex Completes ADS Ratio ChangeOctober 6, 2023 | markets.businessinsider.comAddex To Implement ADS Ratio ChangeOctober 5, 2023 | finance.yahoo.comAddex Therapeutics focused on securing new partnerships to fund promising treatmentsSeptember 25, 2023 | markets.businessinsider.comH.C. Wainwright Reaffirms Their Hold Rating on Addex Therapeutics (ADXN)September 6, 2023 | finance.yahoo.comAddex Announces Participation in the H.C. Wainwright 25th Annual Global Investment ConferenceSeptember 5, 2023 | benzinga.comAddex ADX71149 Phase 2 Epilepsy Study Expected to Readout Data in Q2 2024September 5, 2023 | finance.yahoo.comAddex ADX71149 Phase 2 Epilepsy Study Expected to Readout Data in Q2 2024See More Headlines Receive ADXN Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Addex Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings11/04/2021Today3/28/2024Next Earnings (Estimated)4/04/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:ADXN CUSIPN/A CIK1574232 Webwww.addextherapeutics.com Phone011-41-22-884-1555Fax41-22-884-1556Employees24Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)($19.27) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-21,800,000.00 Net Margins-550.78% Pretax Margin-549.49% Return on Equity-236.83% Return on Assets-147.15% Debt Debt-to-Equity RatioN/A Current Ratio2.97 Quick Ratio2.97 Sales & Book Value Annual Sales$1.51 million Price / Sales8.39 Cash FlowN/A Price / Cash FlowN/A Book Value$8.01 per share Price / Book1.60Miscellaneous Outstanding Shares990,000Free Float843,000Market Cap$12.67 million OptionableNot Optionable Beta1.62 5G Stocks: The Path Forward is ProfitableClick the link below and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise. Get This Free Report Key ExecutivesMr. Timothy Mark Dyer (Age 56)Co-Founder, CEO & Director Dr. Roger G. Mills M.D. (Age 67)Chief Medical Officer & Director Mr. Lénaic Teyssédou (Age 38)Head of Finance Dr. Jean-Philippe Rocher Ph.D. (Age 65)Head of Discovery - Chemistry Dr. Robert Lutjens (Age 56)Head of Discovery - Biology Dr. Mikhail Kalinichev Ph.D. (Age 57)Head of Translational Science More ExecutivesKey CompetitorsJanOneNASDAQ:JANGuardion Health SciencesNASDAQ:GHSIAgeX TherapeuticsNYSE:AGEElevai LabsNASDAQ:ELABEterna TherapeuticsNASDAQ:ERNAView All CompetitorsInstitutional OwnershipJ. Stern & Co. LLPBought 107,827 shares on 2/13/2024Ownership: 10.892%Armistice Capital LLCSold 494,000 shares on 2/13/2024Ownership: 4.343%View All Institutional Transactions ADXN Stock Analysis - Frequently Asked Questions Should I buy or sell Addex Therapeutics stock right now? 1 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Addex Therapeutics in the last year. There are currently 1 hold rating for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" ADXN shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in ADXN, but not buy additional shares or sell existing shares. View ADXN analyst ratings or view top-rated stocks. How have ADXN shares performed in 2024? Addex Therapeutics' stock was trading at $6.05 at the beginning of 2024. Since then, ADXN shares have increased by 111.6% and is now trading at $12.80. View the best growth stocks for 2024 here. Are investors shorting Addex Therapeutics? Addex Therapeutics saw a increase in short interest during the month of March. As of March 15th, there was short interest totaling 11,900 shares, an increase of 41.7% from the February 29th total of 8,400 shares. Based on an average daily trading volume, of 9,600 shares, the days-to-cover ratio is currently 1.2 days. Currently, 1.2% of the shares of the stock are short sold. View Addex Therapeutics' Short Interest. When is Addex Therapeutics' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, April 4th 2024. View our ADXN earnings forecast. How were Addex Therapeutics' earnings last quarter? Addex Therapeutics Ltd (NASDAQ:ADXN) posted its quarterly earnings results on Thursday, November, 4th. The company reported ($14.40) earnings per share (EPS) for the quarter, meeting analysts' consensus estimates of ($14.40). The company had revenue of $0.83 million for the quarter, compared to analysts' expectations of $0.42 million. Addex Therapeutics had a negative trailing twelve-month return on equity of 236.83% and a negative net margin of 550.78%. During the same period in the previous year, the company posted ($15.60) earnings per share. When did Addex Therapeutics' stock split? Addex Therapeutics shares reverse split on Monday, October 23rd 2023. The 1-20 reverse split was announced on Monday, October 23rd 2023. The number of shares owned by shareholders was adjusted after the closing bell on Monday, October 23rd 2023. An investor that had 100 shares of stock prior to the reverse split would have 5 shares after the split. What other stocks do shareholders of Addex Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some companies that other Addex Therapeutics investors own include Achillion Pharmaceuticals (ACHN), ACADIA Pharmaceuticals (ACAD), Arbutus Biopharma (ABUS), Abacus Property Group (ABP), Advanced BioMedical Technologies (ABMT), Abiomed (ABMD), ARCA biopharma (ABIO), Abeona Therapeutics (ABEO) and Abcam (ABCZY). Who are Addex Therapeutics' major shareholders? Addex Therapeutics' stock is owned by many different institutional and retail investors. Top institutional shareholders include J. Stern & Co. LLP (10.89%) and Armistice Capital LLC (4.34%). How do I buy shares of Addex Therapeutics? Shares of ADXN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:ADXN) was last updated on 3/29/2024 by MarketBeat.com Staff From Our PartnersTrump’s “Tax Free” Retirement Strategy Gold Safe ExchangeDid You Get Your Free Bitcoin Yet?Crypto Swap ProfitsTop Project Outperforms BTC in 2023…Crypto 101 MediaMake This $3 Trade the Instant the Opening Bell RingsMonument Traders AllianceAI Cracks Open Largest Untapped Energy Reserve on EarthBanyan Hill PublishingThis AI Trade Machine Made 1,729%* (With 89% Wins)Prosper Trading Academy“The Stock Market’s Bull Run is Far from Over” -BarronsVertical Research AdvisoryAI healthcare stock poised for 36,996% growth?Behind the Markets Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Addex Therapeutics Ltd Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.